Trial Profile
A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) vs. Exemestane (AROMASIN) in Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer With Disease Progression After Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2020
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms EFECT
- Sponsors AstraZeneca
- 16 Jun 2020 Results, a pooled analysis of the phase III SoFEA and EFECT trials, published in the Clinical Cancer Research
- 03 May 2019 Results assess the correlation between serum Thymidine kinase 1 and patient outcome (retrospective analysis) published in the European Journal of Cancer.
- 05 Jun 2018 Results of a retrospective analysis (n=244) assessing the role of serum thymidine kinase-1 (TK1) activity in HR+ advanced breast cancer using serum samples of patients from this study cohort, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.